Trial Profile
An Open-label, Non-randomized Study to Evaluate the Feasibility of [18F]Florbetapir Positron Emission Tomography (PET) for Assessment of Demyelination in Patients With Relapsing Remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Sep 2021
Price :
$35
*
At a glance
- Drugs Florbetapir F 18 (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 25 Aug 2021 Status changed from recruiting to completed.
- 30 Apr 2015 New trial record